Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ELUT
Strong SellSinkerElutia Inc. · Healthcare · United States · $51M · Avg Vol: $44K/d
COMPANY DESCRIPTION
Elutia Inc. develops and commercializes proprietary biologic drug-eluting matrices and regenerative medicine products. The company's competitive moat is secured by its proprietary CanGaroo envelope platform, which delivers targeted antibiotics to prevent surgical site infections. It is a specialized medical device player focused on the high-margin cardiovascular and reconstructive surgery markets.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.8M | 24.7M | 14.5M | 12.3M | -19.8% | 12.1M | 7.5M | 13.1M | 3.2% |
| EPS | -0.64 | -2.07 | -1.86 | 1.29 | — | -0.63 | -0.63 | -0.54 | — |
| Shares | 44.2M | 23.2M | 35.2M | 42.8M | -3.2% | 44.3M | — | — | — |
| Debt | 24.5M | 24.0M | 24.0M | 3.9M | -45.6% | 4.4M | — | — | — |
| Equity | -5.0M | -38.6M | -46.3M | 27.7M | — | — | — | — | — |
| Op CF | -21.4M | -21.8M | -22.7M | -44.8M | — | -44.0M | — | — | — |
| Inv CF | -0.5M | 14.2M | -0.5M | 78.6M | — | — | — | — | — |
| Fin CF | 8.5M | 9.8M | 17.1M | -10.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ELUT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ELUT | Elutia Inc.(you) | $51M | 13 | Strong Sell |
| MDAI | Spectral AI, Inc. | $51M | 12 | Strong Sell |
| COCH | Envoy Medical, Inc. | $53M | 10 | Strong Sell |
| ARAY | Accuray Incorporated | $53M | 19 | Strong Sell |
| SERA | Sera Prognostics, Inc. | $82M | 14 | Strong Sell |
| SRTS | Sensus Healthcare, Inc. | $58M | 22 | Sell |
| HYPR | Hyperfine, Inc. | $88M | 12 | Strong Sell |
| CVRX | CVRx, Inc. | $79M | 9 | Strong Sell |
| LDX.AX | Lumos Diagnostics Holdings Limited | $68M | 3 | Strong Sell |
| RPID | Rapid Micro Biosystems, Inc. | $79M | 6 | Strong Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.3%